=> hcs-pharma.com/qr/wiseed <=
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
Nous avons le plaisir de vous inviter le mercredi 6 juillet 2022 à 18h30 à la prochaine soirée Biotech Agora dédiée à HCS Pharma, en présentiel à l’Hôtel Bedford, 17 rue de l’Arcade, 75008 Paris. HCS Pharma est une Read more…
C’est avec un grand plaisir que nous avons participé à l’étape locale du “Big Tour” de BPI France. La rencontre s’est déroulé à Tourcoing. Cette initiative est destinée à mettre en valeur les entrepreneurs et Read more…
To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route Read more…
It was a pleasure to be invited by the french association France Immersive Learning in the meeting “Immersive technology in health”. We presented our own uses of VR (virtual reality) and AR (augmented reality) in Read more…
It is our pleasure to participate to the ECM2022 congress the 22th, 23th and 24th of June in Copenhagen with two contributions (abstracts at the end): Our project leader in iPSc and Metabolic diseases Meryl Read more…
Thursday, 16th June will take place the annual congress of the SCMC (Societe Cerveau et Maladies Cerebrovasculaires – Brain and cerebrovascular diseases Society) in Paris. It is our pleasure to participate to this event! Indeed, Read more…
Dans le cadre de notre développement, nous recrutons un(e) Technicien(ne) en recherche et développement axée sur des modèles hépatiques in vitro. Vous serez en charge de : Gestion du laboratoire (commandes, entretien des machines, règles HSE, Read more…
L’ingénieur(e) d’étude mettra au point des méthodes expérimentales permettant de développer un modèle tri-dimensionelle de tumeurs colorectales et de prostate avec la technologie Biomimesys développée par HCS Pharma. La technologie de culture BIOMIMESYS® 3D reproduit Read more…
Suite au succès de notre levée de fond sur la plateforme espagnole de crownfunding spécialisée pharma/biotech Capital Cell (2 millions d’euros levés en 24h) et à la consolidation de notre Security Token Offering (STO) sur Read more…
We have the pleasure to introduce to you Michelle Haddad, our new CIFRE PhD student, who will work with us and PETALES laboratory (Procédés Et Transformations Alimentaires et Effets sur la Santé, Transformations & Agroressources, Read more…
When Tuesday, June 28, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 30, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, Read more…
We are very please to annonce our selection in the “CO-INNO INTERNATIONAL” program. Jointly organised by BPI France and Hello Tomorrow, the CO-INNO program accelerates and supports the most cutting-edge French startups from the discovery Read more…
Last week we pleased to welcome in Lille the Molecular Devices’ Imaging User Meeting. It was a amazing opportunities to share our imaging practices with attendees. We presented our services and some of our last Read more…
The current hiPSC-derived models are adapted to reproduce diseases of genetic origin in two dimensions and have allowed in recent years to model diseases by using hepatocyte-like-cells (HCL) such as: Alpha1-antitrypsin (A1AT) deficiency (Tafaleng et Read more…
Last week, we made an astonishing discovery, the world famous Pub Quizz! Thanks to Claramedia company, our team met in a real a french pub, “L’Archétype” in Lille, for a funny contest around general culture, Read more…
We are happy to participate in Cosmetotest, the first Symposium dedicated to preclinical and clinical tests in dermocosmetics the 24th and 25th of May at Lyon. HCS Pharma will be present for the preclinal day, Read more…
When Tuesday, May 31, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 2, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, Read more…
We are pleased to welcome Samantha Glaucie in our laboratory. Samantha obtained her French scientific baccalaureate in 2020 at La Tourelle high school in Sarcelles, in France. Interested in biotechnology, she decided to continue her studies in Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.